The biotech stock's price-to-earnings-to-growth (PEG) ratio is a super-low 0.58, according to the London Stock Exchange Group (LSEG). Any PEG ratio below 1.0 is viewed as an attractive valuation.

Three Motley Fool contributors think they've identified dirt-cheap healthcare stocks to buy right now. Here's why they picked CRISPR Therapeutics (NASDAQ: CRSP), Gilead Sciences (NASDAQ: GILD), and ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

TimesSquare Capital Management, an equity investment management company, released its “U.S. Small Cap Growth Strategy” second ...

Haystack, a leading modern intranet provider, today announced its collaboration with Google Cloud to integrate Google Cloud’s ...

One is that, also in our pain franchise ... And we intend to fully develop both of these markets at Vertex. We see them both as specialty markets. And longer-term, given the mechanism of action, we ...

Vertex Pharmaceuticals (VRTX) closed at $489.43 in the latest trading session, marking a +0.84% move from the prior day. This move outpaced the S&P 500's daily gain of 0.13%. At the same time, the Dow ...

Trinasolar has received an International Design Excellence Award in the US, within the C&I product category, for its Vertex ...

Discover why Vertex stock is undervalued with the potential of VX-548 as a groundbreaking pain treatment drug in the ...

BigEndian Semiconductors, a fabless-semiconductor design startup, raised $3 million in a funding round led by Vertex Ventures SEA & India. The funds will be used to expand the company’s engineering ...

Novo Nordisk is still gaining momentum. There are six great reasons to buy Vertex Pharmaceuticals. There's at least one key common denominator here: tremendous growth prospects. Don't want to ...

In this article, we are going to take a look at where Vertex Pharmaceutical Inc. (NASDAQ ... as well be having a watch party—yes, there was one—but there's nothing to celebrate here.